Asked by dick
How do structural changes from mutations affect function? Provide specific examples.
All Answers 1
Answered by
GPT-5 mini
AI
Mutations change amino acid sequence (or truncate/alter the polypeptide) and so can change a protein’s 3‑D structure, dynamics, interactions and cellular fate. Those structural changes are what usually change function — by altering active‑site geometry, substrate or partner binding, stability and folding, oligomerization, localization, post‑translational modification sites or proteolytic processing. Below is a compact list of the common structural mechanisms plus specific, well‑known examples showing how a structural change causes a functional outcome.
Main structural mechanisms
- Change active‑site geometry or catalytic residues → loss or gain of enzymatic activity.
- Alter stability/folding → misfolding, increased degradation (loss‑of‑function) or aggregation (toxic gain‑of‑function).
- Modify interaction surfaces or oligomerization interfaces → disrupted complex assembly or dominant‑negative effects.
- Change ligand or allosteric binding sites → altered regulation or constitutive activity.
- Remove or create localization/processing signals or PTM sites → mislocalization or altered regulation.
- Truncate chains (nonsense/frameshift) → missing domains and complete loss of function.
Specific examples (mutation → structural change → functional/clinical effect)
1. Sickle cell disease (β‑globin Glu6→Val, “HbS”)
- Structural change: surface Glu (charged) replaced by Val (hydrophobic) creates a hydrophobic patch on deoxygenated hemoglobin.
- Functional effect: hemoglobin tetramers polymerize into fibers that distort red cell shape and reduce oxygen delivery; hemolysis and vaso‑occlusion follow.
2. Cystic fibrosis (CFTR ΔF508)
- Structural change: deletion of Phe508 in NBD1 disrupts domain folding and inter‑domain contacts.
- Functional effect: misfolded CFTR is retained in the ER and degraded (ERAD) rather than trafficking to the plasma membrane → loss of chloride channel function → thick secretions, lung disease.
3. Alpha‑1 antitrypsin deficiency (Z allele, Glu342→Lys / E342K)
- Structural change: substitution destabilizes folding and promotes polymerization of AAT in hepatocyte ER.
- Functional effect: polymers accumulate in liver (hepatitis/cirrhosis) and plasma AAT is deficient, so unchecked neutrophil elastase damages lung tissue → emphysema.
4. Ras oncogene mutants (e.g., Gly12→Val, G12V)
- Structural change: mutation in the GTP‑binding pocket impairs GTP hydrolysis and/or GAP interaction.
- Functional effect: Ras is constitutively GTP‑bound/active → persistent signaling through proliferation pathways → oncogenesis.
5. BRAF V600E (Val600→Glu)
- Structural change: substitution at the activation segment mimics phosphorylation and stabilizes the active kinase conformation.
- Functional effect: constitutive MAPK pathway activation → melanoma and other cancers.
6. p53 DNA‑binding missense mutations (e.g., R175H, R248Q)
- Structural change: destabilize the DNA‑binding domain or alter the DNA contact surface.
- Functional effect: loss of sequence‑specific DNA binding and transcriptional activation of tumor suppressor targets; many mutants also exert dominant‑negative effects on wild‑type p53 tetramers.
7. Duchenne muscular dystrophy (frameshift/nonsense in dystrophin)
- Structural change: frameshift or nonsense mutations produce truncated, nonfunctional dystrophin or induce nonsense‑mediated decay.
- Functional effect: absence of dystrophin destabilizes the muscle membrane → progressive muscle degeneration.
8. Osteogenesis imperfecta (collagen Gly→X substitutions)
- Structural change: replacing any glycine in the Gly‑X‑Y repeat disrupts the tight collagen triple helix packing.
- Functional effect: weak or improperly assembled collagen fibrils → brittle bones and connective‑tissue defects.
9. Phenylketonuria (PAH missense mutations)
- Structural change: many PAH variants either block active‑site geometry or destabilize the folded enzyme.
- Functional effect: reduced phenylalanine hydroxylase activity → accumulation of phenylalanine → neurotoxicity if untreated.
10. Prion diseases (PrP mutations, e.g., D178N)
- Structural change: mutations increase the propensity of the normal α‑rich PrP to convert into β‑rich, aggregation‑prone isoforms.
- Functional effect: formation of amyloid plaques and neurodegeneration (CJD, fatal familial insomnia).
11. Ion‑channel gating defects (e.g., SCN5A ΔKPQ, KCNQ1 mutations)
- Structural change: deletions or substitutions change gating helix conformation or inactivation determinants.
- Functional effect: altered persistent currents or gating → cardiac arrhythmias such as Long QT syndrome.
12. Truncating BRCA1 mutations
- Structural change: premature truncation removes important interaction domains (BRCT, RING).
- Functional effect: loss of DNA repair complex formation → genomic instability and increased breast/ovarian cancer risk.
How to interpret structure→function in practice
- A single amino‑acid change can have small local effects or dramatic global consequences depending on context (active site vs. surface loop vs. buried core).
- Experimental probes: crystallography/NMR/cry‑EM, stability/thermal melts, enzyme kinetics, binding assays, cellular localization and degradation studies reveal the chain from structural change to functional outcome.
- Mutations can be loss‑of‑function, gain‑of‑function, or dominant‑negative — the same structural class can produce different phenotypes depending on the protein’s role and assembly.
If you want, I can:
- Show a structural diagram for one of these examples (e.g., ΔF508 CFTR NBD1 or Glu6→Val in β‑globin),
- Walk through how to predict whether a new missense change will destabilize a protein (sequence conservation, structural context, in silico ΔΔG tools), or
- Give references for structural studies of any example above.
Main structural mechanisms
- Change active‑site geometry or catalytic residues → loss or gain of enzymatic activity.
- Alter stability/folding → misfolding, increased degradation (loss‑of‑function) or aggregation (toxic gain‑of‑function).
- Modify interaction surfaces or oligomerization interfaces → disrupted complex assembly or dominant‑negative effects.
- Change ligand or allosteric binding sites → altered regulation or constitutive activity.
- Remove or create localization/processing signals or PTM sites → mislocalization or altered regulation.
- Truncate chains (nonsense/frameshift) → missing domains and complete loss of function.
Specific examples (mutation → structural change → functional/clinical effect)
1. Sickle cell disease (β‑globin Glu6→Val, “HbS”)
- Structural change: surface Glu (charged) replaced by Val (hydrophobic) creates a hydrophobic patch on deoxygenated hemoglobin.
- Functional effect: hemoglobin tetramers polymerize into fibers that distort red cell shape and reduce oxygen delivery; hemolysis and vaso‑occlusion follow.
2. Cystic fibrosis (CFTR ΔF508)
- Structural change: deletion of Phe508 in NBD1 disrupts domain folding and inter‑domain contacts.
- Functional effect: misfolded CFTR is retained in the ER and degraded (ERAD) rather than trafficking to the plasma membrane → loss of chloride channel function → thick secretions, lung disease.
3. Alpha‑1 antitrypsin deficiency (Z allele, Glu342→Lys / E342K)
- Structural change: substitution destabilizes folding and promotes polymerization of AAT in hepatocyte ER.
- Functional effect: polymers accumulate in liver (hepatitis/cirrhosis) and plasma AAT is deficient, so unchecked neutrophil elastase damages lung tissue → emphysema.
4. Ras oncogene mutants (e.g., Gly12→Val, G12V)
- Structural change: mutation in the GTP‑binding pocket impairs GTP hydrolysis and/or GAP interaction.
- Functional effect: Ras is constitutively GTP‑bound/active → persistent signaling through proliferation pathways → oncogenesis.
5. BRAF V600E (Val600→Glu)
- Structural change: substitution at the activation segment mimics phosphorylation and stabilizes the active kinase conformation.
- Functional effect: constitutive MAPK pathway activation → melanoma and other cancers.
6. p53 DNA‑binding missense mutations (e.g., R175H, R248Q)
- Structural change: destabilize the DNA‑binding domain or alter the DNA contact surface.
- Functional effect: loss of sequence‑specific DNA binding and transcriptional activation of tumor suppressor targets; many mutants also exert dominant‑negative effects on wild‑type p53 tetramers.
7. Duchenne muscular dystrophy (frameshift/nonsense in dystrophin)
- Structural change: frameshift or nonsense mutations produce truncated, nonfunctional dystrophin or induce nonsense‑mediated decay.
- Functional effect: absence of dystrophin destabilizes the muscle membrane → progressive muscle degeneration.
8. Osteogenesis imperfecta (collagen Gly→X substitutions)
- Structural change: replacing any glycine in the Gly‑X‑Y repeat disrupts the tight collagen triple helix packing.
- Functional effect: weak or improperly assembled collagen fibrils → brittle bones and connective‑tissue defects.
9. Phenylketonuria (PAH missense mutations)
- Structural change: many PAH variants either block active‑site geometry or destabilize the folded enzyme.
- Functional effect: reduced phenylalanine hydroxylase activity → accumulation of phenylalanine → neurotoxicity if untreated.
10. Prion diseases (PrP mutations, e.g., D178N)
- Structural change: mutations increase the propensity of the normal α‑rich PrP to convert into β‑rich, aggregation‑prone isoforms.
- Functional effect: formation of amyloid plaques and neurodegeneration (CJD, fatal familial insomnia).
11. Ion‑channel gating defects (e.g., SCN5A ΔKPQ, KCNQ1 mutations)
- Structural change: deletions or substitutions change gating helix conformation or inactivation determinants.
- Functional effect: altered persistent currents or gating → cardiac arrhythmias such as Long QT syndrome.
12. Truncating BRCA1 mutations
- Structural change: premature truncation removes important interaction domains (BRCT, RING).
- Functional effect: loss of DNA repair complex formation → genomic instability and increased breast/ovarian cancer risk.
How to interpret structure→function in practice
- A single amino‑acid change can have small local effects or dramatic global consequences depending on context (active site vs. surface loop vs. buried core).
- Experimental probes: crystallography/NMR/cry‑EM, stability/thermal melts, enzyme kinetics, binding assays, cellular localization and degradation studies reveal the chain from structural change to functional outcome.
- Mutations can be loss‑of‑function, gain‑of‑function, or dominant‑negative — the same structural class can produce different phenotypes depending on the protein’s role and assembly.
If you want, I can:
- Show a structural diagram for one of these examples (e.g., ΔF508 CFTR NBD1 or Glu6→Val in β‑globin),
- Walk through how to predict whether a new missense change will destabilize a protein (sequence conservation, structural context, in silico ΔΔG tools), or
- Give references for structural studies of any example above.
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.